NZ595227A - Tricyclic indole derivates as pbr ligands - Google Patents

Tricyclic indole derivates as pbr ligands

Info

Publication number
NZ595227A
NZ595227A NZ595227A NZ59522710A NZ595227A NZ 595227 A NZ595227 A NZ 595227A NZ 595227 A NZ595227 A NZ 595227A NZ 59522710 A NZ59522710 A NZ 59522710A NZ 595227 A NZ595227 A NZ 595227A
Authority
NZ
New Zealand
Prior art keywords
imaging agent
vivo imaging
synthesis
pbr
tetrahydro
Prior art date
Application number
NZ595227A
Other languages
English (en)
Inventor
Shea Dennis O
Amanda Ewan
Harry John Wadsworth
Bo Shan
Joanna Marie Passmore
William John Trigg
Original Assignee
Ge Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ge Healthcare Ltd filed Critical Ge Healthcare Ltd
Publication of NZ595227A publication Critical patent/NZ595227A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/94—[b, c]- or [b, d]-condensed containing carbocyclic rings other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0446—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0468—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
NZ595227A 2009-03-27 2010-03-26 Tricyclic indole derivates as pbr ligands NZ595227A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16413109P 2009-03-27 2009-03-27
GBGB0905328.1A GB0905328D0 (en) 2009-03-27 2009-03-27 Indole derivatives
PCT/EP2010/053998 WO2010109007A2 (en) 2009-03-27 2010-03-26 Indole derivatives

Publications (1)

Publication Number Publication Date
NZ595227A true NZ595227A (en) 2013-11-29

Family

ID=40671850

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ595227A NZ595227A (en) 2009-03-27 2010-03-26 Tricyclic indole derivates as pbr ligands

Country Status (17)

Country Link
US (2) US8790619B2 (enExample)
EP (1) EP2411362B1 (enExample)
JP (1) JP5651163B2 (enExample)
KR (1) KR101692090B1 (enExample)
CN (1) CN102448933B (enExample)
AU (1) AU2010227527B2 (enExample)
BR (1) BRPI1010261A2 (enExample)
CA (1) CA2756887C (enExample)
ES (1) ES2635310T3 (enExample)
GB (1) GB0905328D0 (enExample)
IL (1) IL215019A0 (enExample)
MX (1) MX2011010154A (enExample)
NZ (1) NZ595227A (enExample)
RU (1) RU2525196C2 (enExample)
SG (1) SG174589A1 (enExample)
WO (1) WO2010109007A2 (enExample)
ZA (1) ZA201106708B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0905328D0 (en) 2009-03-27 2009-05-13 Ge Healthcare Ltd Indole derivatives
CN102834379B (zh) * 2010-03-26 2014-12-24 通用电气健康护理有限公司 作为pbr配体的三环吲哚衍生物
GB201016038D0 (en) 2010-09-24 2010-11-10 Ge Healthcare Ltd In vivo imaging method
GB201016411D0 (en) * 2010-09-30 2010-11-10 Ge Healthcare Ltd In vivo imaging method for cancer
GB201021263D0 (en) * 2010-12-15 2011-01-26 Ge Healthcare Ltd Solid phase extraction method
AU2012240077C1 (en) * 2011-04-05 2017-08-10 Sloan-Kettering Institute For Cancer Research Hsp90 inhibitors
WO2012168697A1 (en) 2011-06-06 2012-12-13 Imperial Innovations Limited Methods to predict binding affinity of tspo imaging agents to tspo
AU2012315757B9 (en) * 2011-09-30 2018-01-25 Ge Healthcare Limited Calibration and normalization systems and methods for radiopharmaceutical synthesizers
RU2015118217A (ru) * 2012-11-30 2017-01-11 ДжиИ ХЕЛТКЕР ЛИМИТЕД Способ кристаллизации трициклических индольных производных
WO2014083163A1 (en) 2012-11-30 2014-06-05 Ge Healthcare Limited Zinc halide mediated cyclization process leading to tricyclic indoles
GB201312768D0 (en) * 2013-07-17 2013-08-28 Ge Healthcare Ltd Work-up procedure
GB201316764D0 (en) * 2013-09-20 2013-11-06 Ge Healthcare Ltd Novel compounds
GB201316766D0 (en) * 2013-09-20 2013-11-06 Ge Healthcare Uk Ltd Macrophage Imaging
GB201316762D0 (en) * 2013-09-20 2013-11-06 Ge Healthcare Ltd Novel compounds
KR102668112B1 (ko) 2014-12-04 2024-05-23 지이 헬쓰케어 리미티드 방사성 약제로부터의 아세트알데히드의 제거 방법
CN106748802B (zh) * 2016-12-26 2018-11-13 南京理工大学 一种制备含氟仲胺的方法
WO2018218025A1 (en) * 2017-05-24 2018-11-29 The Trustees Of The University Of Pennsylvania Radiolabeled and fluorescent parp inhibitors for imaging and radiotherapy
US11200669B2 (en) * 2019-11-19 2021-12-14 Uih America, Inc. Systems and methods for determining plasma input function used in positron emission tomography imaging

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3979391A (en) * 1972-11-22 1976-09-07 Sterling Drug Inc. 1,2,3,4-Tetrahydrocarbazoles
US3939177A (en) * 1972-11-22 1976-02-17 Sterling Drug Inc. 4-Aminomethyl-9-benzyl-1,2,3,4-tetrahydrocarbazoles
FR2599740B1 (fr) * 1986-06-05 1988-08-12 Rhone Poulenc Sante Derives de benzo(b)thiophene de benzo(b)furannecarboxamides, leurs procedes de preparation et les medicaments les contenant
US5270030A (en) * 1988-12-29 1993-12-14 Bio-Technology General Corp. Fibrin binding domain polypeptide and method of producing
JP2001522884A (ja) 1997-11-14 2001-11-20 イーライ・リリー・アンド・カンパニー アルツハイマー病の処置方法
JPH11228539A (ja) * 1997-12-03 1999-08-24 Taisho Pharmaceut Co Ltd 含窒素四環性化合物
DE69814690T2 (de) * 1997-12-03 2004-01-29 Taisho Pharmaceutical Co Ltd Stickstoffenthaltende tetracyclische verbindungen
AU767009B2 (en) * 1998-12-11 2003-10-30 Virginia Commonwealth University Selective 5-HT6 receptor ligands
FR2788776B1 (fr) * 1999-01-26 2001-02-23 Synthelabo Derives de 4-oxo-3, 5-dihydro-4h-pyridazino [4,5-b] indole-1 -carboxamide, leur preparation et leur application en therapeutique
GB0115929D0 (en) 2001-06-29 2001-08-22 Nycomed Amersham Plc Solid-phase electrophilic fluorination
GB0115927D0 (en) 2001-06-29 2001-08-22 Nycomed Amersham Plc Solid-phase nucleophilic fluorination
JP2005527464A (ja) 2001-08-09 2005-09-15 イーライ・リリー・アンド・カンパニー sPLA2インヒビターとしてのシクロヘプタBインドール誘導体
JP2005527466A (ja) 2001-08-09 2005-09-15 イーライ・リリー・アンド・カンパニー sPLA2インヒビターとしてのシクロヘプトBインドール誘導体
GB0523506D0 (en) * 2005-11-18 2005-12-28 Hammersmith Imanet Ltd Novel in vivo imaging compounds
GB0905328D0 (en) 2009-03-27 2009-05-13 Ge Healthcare Ltd Indole derivatives

Also Published As

Publication number Publication date
IL215019A0 (en) 2011-11-30
EP2411362B1 (en) 2017-05-31
US20120020884A1 (en) 2012-01-26
EP2411362A2 (en) 2012-02-01
KR20110133492A (ko) 2011-12-12
US20110070161A1 (en) 2011-03-24
ES2635310T3 (es) 2017-10-03
GB0905328D0 (en) 2009-05-13
CA2756887A1 (en) 2010-09-30
CN102448933B (zh) 2014-07-02
JP2012521973A (ja) 2012-09-20
SG174589A1 (en) 2011-10-28
KR101692090B1 (ko) 2017-01-02
HK1167393A1 (en) 2012-11-30
US8501153B2 (en) 2013-08-06
RU2525196C2 (ru) 2014-08-10
ZA201106708B (en) 2013-02-27
RU2011138850A (ru) 2013-05-10
BRPI1010261A2 (pt) 2016-03-22
WO2010109007A3 (en) 2010-11-25
AU2010227527A1 (en) 2011-10-13
WO2010109007A2 (en) 2010-09-30
MX2011010154A (es) 2011-10-21
AU2010227527B2 (en) 2015-03-12
CN102448933A (zh) 2012-05-09
US8790619B2 (en) 2014-07-29
JP5651163B2 (ja) 2015-01-07
CA2756887C (en) 2018-06-19

Similar Documents

Publication Publication Date Title
WO2010109007A3 (en) Tricyclic indole derivates as pbr ligands
WO2010037851A3 (en) Indole derivatives suitable for imaging neuroinflammation
WO2005040337A3 (en) METHODS FOR BINDING AGENTS TO β-AMYLOID PLAQUES
UA99257C2 (ru) Способ получения 3-замещенных 2-амино-5-галогенбензамидов
HRP20191617T1 (hr) Kombinacija koja sadrži inhibitor mek i inhibitor b-raf
NZ594177A (en) Novel benzodiazepine derivatives
MY150514A (en) Process for preparing 2-amino-5-cyanobenzoic acid derivatives
NZ611988A (en) Solid phase extraction method
MA30950B1 (fr) Nouveaux (aza) cyclohexanes carbonyles en tant que ligands du recepteur de dopamine d3.
MY155478A (en) Process for the regioselective preparation of 1-alkyl-3-haloalkylpyrazole-4-carboxylic acid derivatives
EP4691557A3 (en) Method of synthesizing thyroid hormone analogs and polymorphs thereof
WO2007001958A3 (en) Stereoselective synthesis of amino acid analogs for tumor imaging
IL207895A0 (en) A method for detecting igf1r/chr 15 circulating tumor cells using fish
EP2279759A3 (en) Compounds and methods for 18F labeled agents
MY163136A (en) Peptide radiotracer compositions
PL2918673T3 (pl) Kompozycje do wytwarzania dojrzałych komórek dendrytycznych
WO2011044406A3 (en) Purification method
NZ600800A (en) Purified pyrroloquinolinyl-pyrrolidine-2,5-dione compositions and methods for preparing and using same
NZ602025A (en) Tricyclic indole derivatives as pbr ligands
RU2014109381A (ru) СПОСОБ ПОЛУЧЕНИЯ КОМПЛЕКСОВ 68Ga
WO2007021858A3 (en) Methods of making radiolabeled tracers and precursors thereof
TW200720366A (en) Process for preparing metal compounds of an azo compound in the presence of seed crystals
NI201000144A (es) Procedimiento de preparación de combretastatina
TW200833371A (en) Process for solid formulations
IL180311A0 (en) Process for the preparation of 4,4-difluoro-3-oxobutanoic acid esters

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 26 MAR 2017 BY COMPUTER PACKAGES INC

Effective date: 20140328

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 MAR 2018 BY COMPUTER PACKAGES INC

Effective date: 20170302

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 MAR 2019 BY COMPUTER PACKAGES INC

Effective date: 20180302

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 MAR 2020 BY ANAQUA SERVICES

Effective date: 20190219

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 MAR 2021 BY ANAQUA SERVICES

Effective date: 20200219

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 MAR 2022 BY ANAQUA SERVICES

Effective date: 20210217

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 MAR 2023 BY ANAQUA SERVICES

Effective date: 20220218

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 MAR 2024 BY ANAQUA SERVICES

Effective date: 20230222

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 MAR 2025 BY ANAQUA SERVICES

Effective date: 20240220

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 MAR 2026 BY ANAQUA SERVICES

Effective date: 20250219

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 MAR 2027 BY ANAQUA SERVICES

Effective date: 20260220